Teva calls Pfizer patent violation allegations 'baseless'

By Ted A. Knutson

Washington, Feb. 9 - Teva Pharmaceutical Industries Ltd. said Thursday that allegations that Teva's generic version of Pfizer's drug Zithromax (azithromycin dihydrate) violates a patent are "baseless."

On Wednesday, Pfizer said it was filing a citizen petition with the Food and Drug Administration asking that the Teva generic be recalled. Pfizer also filed a patent infringement lawsuit.

Teva said it has not seen the petition or the lawsuit.

Teva said its azithromycin is a self developed product and is protected by U.S. Patent No. 6,365,574 issued and assigned to Teva on April 2, 2002.

Teva is a Jerusalem, Israel-based pharmaceutical giant.

Pfizer is a New York-based drug company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.